Cargando…
SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479347/ https://www.ncbi.nlm.nih.gov/pubmed/36109713 http://dx.doi.org/10.1186/s12916-022-02547-2 |
_version_ | 1784790769291231232 |
---|---|
author | Karachaliou, Marianna Moncunill, Gemma Espinosa, Ana Castaño-Vinyals, Gemma Rubio, Rocío Vidal, Marta Jiménez, Alfons Prados, Esther Carreras, Anna Cortés, Beatriz Blay, Natàlia Bañuls, Marc Pleguezuelos, Vanessa Melero, Natalia Rodrigo Serra, Pau Parras, Daniel Izquierdo, Luis Santamaría, Pere Carolis, Carlo Papantoniou, Kyriaki Goldberg, Ximena Aguilar, Ruth Garcia-Aymerich, Judith de Cid, Rafael Kogevinas, Manolis Dobaño, Carlota |
author_facet | Karachaliou, Marianna Moncunill, Gemma Espinosa, Ana Castaño-Vinyals, Gemma Rubio, Rocío Vidal, Marta Jiménez, Alfons Prados, Esther Carreras, Anna Cortés, Beatriz Blay, Natàlia Bañuls, Marc Pleguezuelos, Vanessa Melero, Natalia Rodrigo Serra, Pau Parras, Daniel Izquierdo, Luis Santamaría, Pere Carolis, Carlo Papantoniou, Kyriaki Goldberg, Ximena Aguilar, Ruth Garcia-Aymerich, Judith de Cid, Rafael Kogevinas, Manolis Dobaño, Carlota |
author_sort | Karachaliou, Marianna |
collection | PubMed |
description | BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of a cohort study in Catalonia between June and November 2020 and a second time between May and July 2021. Questionnaire data and electronic health records on vaccination and COVID-19 testing were available in both periods. Data on several lifestyle, health-related, and sociodemographic characteristics were also available. RESULTS: Antibody seroreversion occurred in 35.8% of the 64 participants non-vaccinated and infected almost a year ago and was related to asymptomatic infection, age above 60 years, and smoking. Moreover, the analysis on kinetics revealed that among all responses, IgG RBD, IgA RBD, and IgG S2 decreased less within 1 year after infection. Among vaccinated, 2.1% did not present antibodies at the time of testing and approximately 1% had breakthrough infections post-vaccination. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent. In previously infected individuals, vaccination boosted the immune response and there was a slight but statistically significant increase in responses after a 2nd compared to the 1st dose. Infected vaccinated participants had superior antibody levels across time compared to naïve-vaccinated people. mRNA vaccines and, particularly the Spikevax, induced higher antibodies after 1st and 2nd doses compared to Vaxzevria or Janssen COVID-19 vaccines. In multivariable regression analyses, antibody responses after vaccination were predicted by the type of vaccine, infection age, sex, smoking, and mental and cardiovascular diseases. CONCLUSIONS: Our data support that infected people would benefit from vaccination. Results also indicate that hybrid immunity results in superior antibody responses and infection-naïve people would need a booster dose earlier than previously infected people. Mental diseases are associated with less efficient responses to vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02547-2. |
format | Online Article Text |
id | pubmed-9479347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94793472022-09-17 SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia Karachaliou, Marianna Moncunill, Gemma Espinosa, Ana Castaño-Vinyals, Gemma Rubio, Rocío Vidal, Marta Jiménez, Alfons Prados, Esther Carreras, Anna Cortés, Beatriz Blay, Natàlia Bañuls, Marc Pleguezuelos, Vanessa Melero, Natalia Rodrigo Serra, Pau Parras, Daniel Izquierdo, Luis Santamaría, Pere Carolis, Carlo Papantoniou, Kyriaki Goldberg, Ximena Aguilar, Ruth Garcia-Aymerich, Judith de Cid, Rafael Kogevinas, Manolis Dobaño, Carlota BMC Med Research Article BACKGROUND: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. METHODS: We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of a cohort study in Catalonia between June and November 2020 and a second time between May and July 2021. Questionnaire data and electronic health records on vaccination and COVID-19 testing were available in both periods. Data on several lifestyle, health-related, and sociodemographic characteristics were also available. RESULTS: Antibody seroreversion occurred in 35.8% of the 64 participants non-vaccinated and infected almost a year ago and was related to asymptomatic infection, age above 60 years, and smoking. Moreover, the analysis on kinetics revealed that among all responses, IgG RBD, IgA RBD, and IgG S2 decreased less within 1 year after infection. Among vaccinated, 2.1% did not present antibodies at the time of testing and approximately 1% had breakthrough infections post-vaccination. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent. In previously infected individuals, vaccination boosted the immune response and there was a slight but statistically significant increase in responses after a 2nd compared to the 1st dose. Infected vaccinated participants had superior antibody levels across time compared to naïve-vaccinated people. mRNA vaccines and, particularly the Spikevax, induced higher antibodies after 1st and 2nd doses compared to Vaxzevria or Janssen COVID-19 vaccines. In multivariable regression analyses, antibody responses after vaccination were predicted by the type of vaccine, infection age, sex, smoking, and mental and cardiovascular diseases. CONCLUSIONS: Our data support that infected people would benefit from vaccination. Results also indicate that hybrid immunity results in superior antibody responses and infection-naïve people would need a booster dose earlier than previously infected people. Mental diseases are associated with less efficient responses to vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02547-2. BioMed Central 2022-09-16 /pmc/articles/PMC9479347/ /pubmed/36109713 http://dx.doi.org/10.1186/s12916-022-02547-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Karachaliou, Marianna Moncunill, Gemma Espinosa, Ana Castaño-Vinyals, Gemma Rubio, Rocío Vidal, Marta Jiménez, Alfons Prados, Esther Carreras, Anna Cortés, Beatriz Blay, Natàlia Bañuls, Marc Pleguezuelos, Vanessa Melero, Natalia Rodrigo Serra, Pau Parras, Daniel Izquierdo, Luis Santamaría, Pere Carolis, Carlo Papantoniou, Kyriaki Goldberg, Ximena Aguilar, Ruth Garcia-Aymerich, Judith de Cid, Rafael Kogevinas, Manolis Dobaño, Carlota SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title_full | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title_fullStr | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title_full_unstemmed | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title_short | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia |
title_sort | sars-cov-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in catalonia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479347/ https://www.ncbi.nlm.nih.gov/pubmed/36109713 http://dx.doi.org/10.1186/s12916-022-02547-2 |
work_keys_str_mv | AT karachalioumarianna sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT moncunillgemma sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT espinosaana sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT castanovinyalsgemma sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT rubiorocio sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT vidalmarta sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT jimenezalfons sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT pradosesther sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT carrerasanna sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT cortesbeatriz sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT blaynatalia sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT banulsmarc sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT pleguezuelosvanessa sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT meleronataliarodrigo sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT serrapau sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT parrasdaniel sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT izquierdoluis sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT santamariapere sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT caroliscarlo sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT papantonioukyriaki sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT goldbergximena sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT aguilarruth sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT garciaaymerichjudith sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT decidrafael sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT kogevinasmanolis sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia AT dobanocarlota sarscov2infectionvaccinationandantibodyresponsetrajectoriesinadultsacohortstudyincatalonia |